Sionna Therapeutics, Inc. Common Stock (SION) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sionna Therapeutics, Inc. Common Stock (SION) has a cash flow conversion efficiency ratio of -0.054x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.63 Million) by net assets ($306.83 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Sionna Therapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how Sionna Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Sionna Therapeutics, Inc. Common Stock for a breakdown of total debt and financial obligations.
Sionna Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sionna Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513
|
0.021x |
|
Shriram Pistons & Rings Limited
NSE:SHRIPISTON
|
0.100x |
|
Devyani International Limited
NSE:DEVYANI
|
0.095x |
|
Snowsky Salt Industry Group Co Ltd
SHG:600929
|
0.021x |
|
Zhejiang CONBA Pharmaceutical Co Ltd
SHG:600572
|
0.019x |
|
Dis-Chem Pharmacies
JSE:DCP
|
0.341x |
|
Medicover AB (publ)
ST:MCOV-B
|
0.170x |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
0.009x |
Annual Cash Flow Conversion Efficiency for Sionna Therapeutics, Inc. Common Stock (2022–2025)
The table below shows the annual cash flow conversion efficiency of Sionna Therapeutics, Inc. Common Stock from 2022 to 2025. For the full company profile with market capitalisation and key ratios, see SION market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $306.83 Million | $-66.30 Million | -0.216x | -167.01% |
| 2024-12-31 | $-163.71 Million | $-52.79 Million | 0.322x | -15.23% |
| 2023-12-31 | $-114.88 Million | $-43.70 Million | 0.380x | -26.26% |
| 2022-12-31 | $-69.92 Million | $-36.07 Million | 0.516x | -- |
About Sionna Therapeutics, Inc. Common Stock
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109,… Read more